Clinical Edge Journal Scan

Rheumatoid arthritis: Olokizumab shows promise in phase 3


 

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1 , a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876 .

Recommended Reading

RA: IL-6i with or without T-cell inhibitors lowers T2DM risk
MDedge Rheumatology
Risk factors for VTE and ASCVD in patients with RA
MDedge Rheumatology
Incidence of dementia appears to be declining over time in patients with RA
MDedge Rheumatology
HBV screening often incomplete or forgone when starting tocilizumab, tofacitinib
MDedge Rheumatology
Can a blood-based test predict TNFi nonresponse in RA?
MDedge Rheumatology
Tocilizumab shortage continues as pandemic wears on
MDedge Rheumatology
New options explored for sarcopenia in rheumatic diseases
MDedge Rheumatology
Parental smoking linked to more adult RA in women
MDedge Rheumatology
In RA patients, multiple comorbidities lower odds of disease control
MDedge Rheumatology
NIH to study COVID vaccine booster in people with autoimmune disease
MDedge Rheumatology